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SAMMANFATTNING 
Det söks efter alternativ till antibiotika eftersom dess användbarhet mot resistenta bakterier är 
begränsad och användningen kan ge negativa biverkningar. Ett alternativ som utforskas är 
användning av fager. Fagterapi har varit känd i över hundra år och används även i några 
länder. Det är viktigt att använda lytiska fager då temperata fager kan ge resistens och sprida 
virulens bland infekterade bakterier. Bakterien Staphylococcus aureus (S. aureus) är en viktig 
patogen med ökande antibiotikaresistentproblematik. Syftet med uppsatsen var att undersöka 
tillgänglig litteratur och besvara frågan: “finns det tillräckligt med vetenskaplig forskning för 
att använda fager som terapi mot S. aureus i klinik”? Det gjordes genom att söka efter 
relaterade artiklar i databasen PubMed. Där ett antal av 6983 hittades av vilka 990 stycken var 
review artiklar. Majoriteten av genomgångna artiklar visar på baktericida effekter av 
fagterapi. De täckte ett brett spektrum av användningsområden med översyn av fagterapi för 
mastit på kor, biofilm av bakterier, septikemi, S. aureus infektion efter ortopedisk kirurgi, 
bakteriemi, MultiDrug- och Methicillinresistens samt endoftalmit. Försök hade utförts in vitro 
samt in vivo på försöksdjur liksom i fältförsök. Fag-cocktails från den ryska marknaden 
påvisade baktericid effekt på humana stammar av S. aureus samtidigt som den baktericida 
effekten på stammar från gris var begränsad. Behandling med fagterapi av S. aureus från 
mjölkkor med mastit påvisade baktericid effekt vid laboratorietester på möss. Däremot kunde 
inte fältförsöket på kor med subklinisk mastitinfektion visa att fagterapin hade signifikant 
ökad baktericid effekt jämfört med kontrollgruppen. Andra försök har gjorts för att utvärdera 
fagterapi som möjlig del av lösningen mot biofilm i miljö liksom vid ortopediska ingrepp. 
Försöken utfördes in vitro, liksom i möss-, kanin- och fårmodeller. Med resultat som visade 
på baktericid verkan både vid kombinerad behandling med andra antibakteriella medel och 
som möjlig intervention för att begränsa bakterietrycket. Sammanfattningsvis har det visats att 
fagterapi har baktericid effect mot S. aureus både in vitro och in vivo i laboratorieförsök. 
Även om fältförsöket på kor med subklinisk mastit inte kunde påvisa signifikant baktericid 
effekt till förmån för fagterpi framför kontrollgrupp. Samtidigt finns det i till exempel 
Ryssland, Georgien, USA och Kina en marknad med medicinska produkter som gör det 
möjligt att använda fagterpi i klinik. 
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SUMMARY 
Alternatives to antibiotics are being searched for since their efficacy on resistant bacteria is 
limited and using it can give negative side effects. One alternative that is being researched is 
the use of phages. Phage therapy has been known for about one hundred years and is also 
being used in some countries. It is important to use lytic phages for temperate phages might 
spread resistance and transfer virulence factors among infected bacteria. The bacteria 
Staphylococcus aureus (S. aureus) is an important pathogen with increasing resistance 
problem to antibiotics. The aim of this study was to investigate the available literature and 
answer the question: ´is there enough scientifically based research done to use therapy with 
phages against S. aureus in clinic´? The answers were found by searching for related articles 
in the database PubMed. Where a number of 6983 published articles were obtained of which 
990 were review articles. The large majority of included articles in this review showed 
bactericidal effects from phage therapy. They had a broad coverage on looking into phage 
therapy against diseases as mastitis in cows, biofilm layers, septicaemia, S. aureus infection 
following orthopaedic surgery, bacteremia, MultiDrug- and Methicillin resistance and 
endophthalmitis. Trials have been conducted in vitro and in vivo on laboratory animals as well 
as in field. Phage cocktails on the market in Russia proved to be bactericidal on human S. 
aureus strains and meanwhile showing limited bactericidal effect on porcine strains. 
Treatment with phages of mastitis S. aureus from dairy cows had bactericidal effects in 
treating infected laboratory mice. The field trial on cows with subclinical mastitis infection on 
the other hand could not show that treatment with phage therapy had significantly higher 
levels of bactericidal effect compared to the control group. Attempts have been made to 
evaluate if phage therapy might be a part of the solution of biofilm in environment and in 
orthopaedic surgery. These trials were conducted in vitro as well as in mice, rabbit and sheep 
models. With results showing its efficacy as combined treatment with other antibacterial 
agents and as a possible intervention to decrease bacterial load. The conclusion drawn from 
this is that phage therapy has achieved bactericidal effects against S. aureus in vitro and in 
vivo on laboratory level. The field trial found on cows with subclinical mastitis could not 
confirm significant bactericidal effect in favour of phage treatment to controls though. 
Meanwhile in Russia, Georgia, US and China for example, phages are medical products on 
the market and available for use in clinic.  
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INTRODUCTION 
Staphylococcus aureus (S. aureus) is a Gram-positive bacterium, also known as the ´golden 
staph´ due to the characteristic yellow pigment production (Lan et al., 2010). It is considered 
a commensal and opportunist in humans since about 20 - 30 % of the population are carriers 
(Gorwitz et al., 2008). Nonetheless, S. aureus can cause serious infections in both humans and 
animals with fatal consequences as well as food poisoning (Quinn, 2011). In dairy cows S. 
aureus can be the reason to mastitis, an infection in the udder of the cow. Leading to pain and 
suffering of the animal along with economic losses for the owner and industry (Anderson et 
al., 2012).  
Antibiotics was first used in large scale in the 1940s and saved millions of lives. Shortly 
thereafter isolates emerged that were resistant to penicillin. As to S. aureus, short after the 
semisynthetic penicillin methicillin got out on the market, resistant strains emerged and the 
MultiResistant S.aureus (MRSA) spread (Aminov, 2010). Recent studies also raise anxiety on 
the collateral damage antibiotics can do to the microbiota (Modi et al., 2014).  
New antibiotics need to be developed as well as alternative methods in treating bacterial 
infections (Lee et al., 2013). One of these methods might be ´phage therapy´. Phages, or 
bacteriophages, are virus that can infect and eventually kill bacteria. They were detected 
around 100 years ago and have a history of medical use in many countries. The phage therapy 
has with antibiotic resistance met a renaissance (Abedon et al., 2011). Phages that infect S. 
aureus, are of the order Caudovirales -viruses with tails (Xia & Wolz, 2014). They are DNA 
viruses of Podovidridae, Siphoviridae or Myoviridae families (Ackermann, 2009). Phages can 
be virulent (lytic) and kill bacteria or temperate and integrate into the bacterial genome (see 
Fig. 1). For therapy only virulent phages are suitable to use, the temperate ones may help 
bacteria to avoid future phage infections and might carry virulence factors making the bacteria 
more capable of causing disease (Carter, 2013). 
 
  
Figure 1. Schematic view on how virulent Caudovirales phage to the left and temperate 
Caudovirales phage to the right affect S. aureus bacteria. 
OBJECTIVE AND MATERIALS 
The aim of this paper was to investigate the literature on the subject phage therapy against S. 
aureus. The objective was to eventually answer the question: ´is there enough scientifically 
based research done to use therapy with phages against S. aureus in clinic´?   
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A research in the database archives of PubMed was made. The search terms bacteriophage 
OR phage AND S. aureus OR Staph aureus OR Staphylococcus aureus AND therapy OR 
therapeutics* OR treatment OR therapies OR practice OR treat* with filter “Other animals” 
and “Humans” gave as a result 6983 items, of which, 990 were review articles. A selection of 
articles were made by date, topics and based on their ability to answer to the aim of the 
objective of this paper. 
LITERATURE OVERVIEW AND RESULTS  
Phage therapy for S. aureus 
Several studies have proven by in vitro models that phages have bactericidal effects against S. 
aureus. For example the two research teams Leskinen et al., (2017) and Rahman et al., (2011) 
demonstrated this with in vitro models. Leskinen et al., (2017) showed that phage a ´cocktail´ 
named fRuSau02 had lytic impact and the ability to kill 135 S. aureus strains of human origin. 
However this phage ´cocktail´ showed very limited bactericidal effect on the 54 S. aureus 
strains of the porcine origin tested with only 30 % sensitivity and infectivity (Leskinen et al., 
2017). Rahman et al., (2011) got the same conclusion of bactericidal reaction on 43 strains of 
S. aureus of human clinical isolates in combination with the antibacterial agent Rifampicin.  
Phage ´cocktail´ fRuSau02 came from a producer in Russia. Leskinen et al., (2017) ran 
laboratory in vitro tests on 135 human S. aureus strains of which some were MRSA. These 
strains came directly from infected patients who were in contact with healthcare. On the other 
hand when this same ´cocktail´ was used on S. aureus strains of porcine origin only 30 % (of 
54 strains) were sensitive (Leskinen et al., 2017). 
Phage SAP26 is of the family Siphoviridae. Rahman et al., (2011) verified its lytic effect on 
110 MRSA and 61 MSSA isolates. To further examine its possibility to be used on biofilm 
formations an experiment comparing phage therapy to other antibacterial agents were run. 
The antibacterial agents used were Azitromycin, Vancomycin and Rifampicin. These were 
compared to each other and in combinations with phage SAP26. In addition one group was 
tested to the phage alone. This test showed that the phage SAP26 alone could kill 28% of the 
bacteria in 24 h. Thus, when combined with Rifampicin 40 % of the bacterial cells died within 
24 h. The combination of SAP26 and Rifampicin was the highest bactericidal effect obtained 
(Rahman et al., 2011).  
Following the in vitro trials several laboratory tests have been done using mice as model 
animals. Mostly researchers conclude phage therapy to be safe and showing bactericidal 
effects, others are contradictory. For although both Gupta & Prasad (2011) and Singh et al., 
(2014) conclude that phage therapy can be safely tested against MRSA strains there are other 
studies showing negative side effects. In a safety trial by Breyne et al., (2017) uninfected and 
healthy mice were injected with phages in their mammary glands. When evaluating this they 
found that necrosis had emerged in the tissue and could be seen in histology sections (Breyne 
et al., 2017).  
When Gupta & Prasad, (2011) used phage P-27/HP to show its therapeutic value on 
Methicillin resistant S. aureus 27/HP they used bacteria from human patients. Their test was 
run in a mouse model. There were three groups of five mice (n=5) in each 1: positive control, 
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2: experimental group and 3: negative control group. A rate of 100% survival in the 
experimental group and reduction of splenic S. aureus 27/HP advocates the advantage of P-
27/HP for this strain (Gupta & Prasad, 2011).  
Singh et al., (2014) on the other hand wanted to investigate the possibility to treat purulent 
eye infections, endophthalmitis, caused by S. aureus with phage therapy. They used 10 mice 
that were infected through infection of their eyes with S. aureus strain RN6390. This was a 
methicillin sensitive strain. Thereafter they were treated with phage Ply187 one single time. 
Results gave that leukocyte infiltration was reduced in comparison to a control group of mice 
eyes and that staphylolytic effect was obtained. An additive result from the mice trial was a 
reduction of retinal cell damage that S. aureus bacterial toxins generate. During preparation 
for this trial in vitro study of phage Ply187 on methicillin resistant and several other S. aureus 
strains was conducted, showing staphylolytic activities as well. In conclusion the authors find 
their result comfortable for future test with Ply187 on endophthalmitis caused by MRSA 
strains (Singh et al., 2014). All articles reviewed in this paper are schematically demonstrated 
in Table 1.   
Phage therapy and mastitis in cows  
Several studies have been arranged to try phage therapy on mastitis caused by S. aureus in 
cows. Iwano et al. (2018) have shown, in a mouse model, that phage ΦSA012 and phage 
ΦSA039 of the family Myoviridae can be effectively used on 93 S. aureus strains. The 
bacteria (S. aureus) were found in dairy cows with mastitis. Mammary glands of lactating 
mice were inoculated with the suspension containing S. aureus. The pups were only separated 
from their mothers during this procedure thereafter they were kept together throughout the 
time of the experiment. The result was that phage therapy decreased infection and 
proliferation of S. aureus when administered at a multiplicity of 100 compared to the bacterial 
load of the infection. Treatment with phages gave a statistically significant difference with 
less bacterial colony-forming units (CFU) in mammary gland compared to controls two days 
after the therapy. In addition intraperitoneal route proved to be more efficient than intra 
mammary or intravenous (Iwano et al., 2018).  
Yet another study run by Breyne et al., (2017) tried almost the same with S. aureus N305 
strain and both Myovirus phage ATCC 23361 and BP39. This specific bacterial strain is used 
in experiments as isolate from dairy cows mastitis. Phage ATCC 23361 were evolved by the 
laboratory team and phage BP39 came from PhageLux, a company that holds a genebank of 
phages. Lactating mice were infected and treated with phage as examination group, 
cefalonium as positive control group (a first generation cephalosporin antibiotics) or 
phosphate buffer saline as negative control group. The mammary glands were inoculated of 
lactating mice through the teat canal, a small cut had to be done in each teat for entering the 
needle. At the end of the experiment the animals were euthanized and examined. Bactericidal 
effects could be confirmed with phage therapy treated bacterial load at significant levels lower 
than the negative control group. The numbers of CFU for phage therapy group were at 6,16 
log10 CFU/ gram compared to the negative control group at 8,17 log10 CFU/ gram. As a result 
they made clear that phage therapy could be an alternative to antibiotics (Breyne et al., 2017). 
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On the contrary from highly bactericidal effects in vitro and in laboratory animals models Gill 
et al. (2006) conclude from a placebo-control and multisite study that bacteriophage treatment 
of subclinical mastitis against S. aureus was limited. The animals included were dairy cows 
from seven different farms. An exclusion criterion was that they had recently been treated 
with antibiotics. The phage used was bacteriophage K. The treatment group consisted of 13 
animals with a total of 18 affected udder quarters and the placebo group included 11 cows 
with 20 affected udder quarters. Administration route was intramammary infusion directly 
after milking the udder, followed by massage to circulate the content and transport the 
solution within the udder. Three udder quarters (3/18) in the bacteriophage treatment group 
were cured and no S. aureus detected four weeks post treatment. The placebo group held no 
cured udder quarters (0/20). This difference in result did not reach statistically significant 
levels. As this was a field trial it had a higher value of its results and was closer to clinical 
work than the others referred to on the subject mastitis by S. aureus in cows (Gill et al., 
2006).  
Phage therapy in septicaemia and bacteraemia  
Additional research on phage therapy against S. aureus has been made to evaluate its action 
on septicaemia and bacteraemia. Takemura-Uchiyama et al., (2014) explored if bacteriophage 
S13´ was accurate to cure lung-derived septicaemia. The strain SA27 of S. aureus was used 
on neutropenic mice, individuals with reduced immune system capacity. This phage is from 
family Podoviridae and had been tried out to be bactericidal in vitro before the clinical trial 
started. During the in vivo part of the test inoculation was made through the intranasal route, 
which caused suffocation and death to some animals. Surviving individuals were included in 
the experiment and results. Bacterial concentrations were examined from blood, lungs, spleen 
and liver. There was a difference in survival rate at 67%, to 10 % in the negative control 
group, in favour of the phage treatment (Takemura-Uchiyama et al., 2014).  
Phage therapy has also been tested against bacteraemia. In one study by Oduor et al., (2016) 
S. aureus of a MultiDrugResistant Staphylococcus aureus (MDRSA) strain was injected into 
mice through their tail vein. The phage was obtained from the environment and sought for in 
wastewater and sewage. An in vitro test was performed before starting the experiment to 
control the capability of the phages to lysate this MDRSA. There were 30 animals included 
and five individuals were left uninfected as controls. The groups treated included 1: 
clindamycin 2: phage therapy, 3: clindamycin and phage therapy 4: untreated negative 
controls. Within 9 days post treatment of phage therapy bacteraemia in bloodstream had been 
cured and no bacteria could be detected. This was far better than the clindamycin treated 
groups that had bacteria in blood samples with MDRSA10 days post treatment. The 
difference was significant in favour of phage therapy (Oduor et al., 2016).  
Phage therapy on biofilm and orthopaedic surgery  
Biofilm formation is a problem in hospital environment and S. aureus is one part of this 
problem (Archer et al. 2011). This specific bacterium is also a complicating factor after 
orthopaedic surgery (Ibid). Numerous attempts have been made to see if phage therapy might 
be a component of the solution. These trials have been conducted in vitro, as well as in mice, 
rabbit and sheep models.  
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While one study by Kaur et al., (2016) showed that phage therapy decreased bacterial load the 
most when combined with another antibacterial agent. Both Drilling et al., (2014), Lungren et 
al., (2014) and Hsieh et al., (2011) found that phages alone had impact and bactericidal effect 
on biofilm and bacteraemia infection derived from such. All trials were conducted in animal 
models. 
In the study by Kaur et al., (2016) phage therapy was used against S. aureus ATCC43300 
during surgery. This strain of bacteria is methicillin resistant. The orthopaedic surgery was 
performed on 30 mice where the medullary canal of the thighbone (femur) was introduced 
with a K-wire. After this was done the bacteria was inoculated, as to simulate an infection 
post surgery. They compared five groups respectively. By day 10 the bacterial load in joint 
tissue in groups with combined antibacterial agent and phages had gone down to zero. While 
groups with naked wire or only hydroxopropyl methylcellulose on the wire still by day 10 
carried bacteria in joint tissue. The difference in groups with phages had significantly 
decreased bacterial load (Kaur et al., 2016).  
On the other hand in the study by Lungren et al., (2014) 10 rabbits were included. The 
bacterium S. aureus of strain 46106, a methicillin sensitive strain of human origin was used. It 
was a randomised trial where all animals had a central venous catheters surgically induced. In 
the control group (5 individuals) all animals were maintained untreated and they all had 
biofilm presented at the catheters. Meanwhile, in the experimental group, that was treated 
with bacteriophage K, only one of five (1/5) exposed biofilm formation. The difference in 
bacterial load between the two groups was significant. In conclusion they lift that this 
reduction of biofilm is noteworthy and that future in vitro studies must foresee the importance 
of enough phage density in the target bacteria (Lungren et al., 2014).  
In the trial done by Drilling et al., (2014) sheep were the animal model. Their aim was to 
evaluate and control the safety of phage therapy on biofilm of S. aureus. The strain used was 
ATCC25923 and the phage used was a mixture of S. aureus specific bacteriophage. The trial 
included four groups of three individuals in each treated as follows 1: no treatment, 2: 
ethylenediaminetetraacetid acid (EDTA), 3: cocktail of S. aureus specific phages (CTSA) and 
4: CTSA + EDTA. The sheep were inoculated to cause a manifest infection and produce 
biofilm layer in the frontal sinuses. The conclusion was that the phage cocktail was safe to use 
and that the treatment reduced the number of bacteria in the biofilm. With no significant 
inflammation or damage to mucosal cilia between the groups, indicating noteworthy EDTA 
treatment to be safe and effective as well (Drilling et al., 2014).  
Hsieh et al., (2011) performed a contamination test with S. aureus. They used isolates from 
human patients found on endotracheal tubes. The test was run with mice as model animals. 
The lytic phage (Stau2) was used. Stau2 is a member of the Myoviridae family. The strain 
S23 of S. aureus was induced via intraperitoneal injection. This specific strain is a MRSA 
isolate. It was studied first in vitro together with isolate of the phage to confirm that Stau2 
possessed lytic ability on the bacteria. These tests showed that Stau2 had bactericid effect on 
80 % of S. aureus isolates found on endotracheal tubes from patients. Without treatment the 
S23 infected mice died. Another 25 mice were treated with the phage Stau2 in different 
concentrations. The phage treated mice had full protection when treated with a 10 fold dose 
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(multiplicity of infection 10) of Stau2 to the induced dose of S. aureus, when treated 
immediately after the inoculation. The authors suggest this specific phage to be used against 
skin infections or in food industry on S. aureus including MRSA strains (Hsieh et al., 2011).  
Table 1. Overview of included articles: – means limited bactericidal effects, (+) means 
bactericidal effects, indication of risk and + means bactericidal effects. 
Bacterial strain etiology Model Results Authors 
Human clinical isolates In vitro + Leskinen et al. (2007) 
Porcine In vitro - Leskinen et al. (2007) 
Mastitis cows Mouse + Iwano et al. (2018) 
Mastitis cows Mouse (+) Breyne et al. (2007) 
Mastitis cows Cow - Gill et al. (2006) 
Methillin resistant human 
isolates 
Mouse + Takemura-Uchiyama et al. 
(2014) 
Human clinical isolate In vitro + Rahman et al. (2011) 
Methillin resistant human 
isolates 
Mouse + Kaur et al. (2016) 
Human clinical isolate Rabbit + Lungren et al. (2014) 
Wastewater, MultiDrug 
resistance 
Mouse + Oduor et al. (2016) 
Methillin sensitive and 
resistant human clinical 
isolates 
Mouse + Hsieh et al. (2011) 
Methillin resistant human 
isolates 
Mouse + Gupta & Prasad (2011) 
Methillin sensitive and 
resistant human isolates 
Mouse + Singh et al. (2014) 
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DISCUSSION  
Discussion on results  
The problem with phage being temperate and integrating to replicate with the bacteria have 
been discussed. Leskinen et al., (2017) mentioned this in their report. It might have been a 
possible reason to why the porcine strains of S. aureus were more resistant to the fRuSau02 
phage ´cocktail´ than the human strains. Leskinen et al., (2017) suggests that the pig´s 
environment may have presented temperate phages to the bacteria. That was not being 
proven; nevertheless it could have been the reason to their resistance. Also Menouni et al. 
(2015) stresses this to be a complicating factor. By remodelling the bacterial genome phages 
can help them to become more capable of resisting the therapy (Menouni et al., 2015).  
Reported studies of phage therapy in mastitis caused by S. aureus gave a diverged picture. 
Both studies on mice quoted here gave bactericidal results (Breyne et al., 2017; Iwano et al., 
2018). On the other hand the field trial study by Gill et al. (2006) on dairy cows got other 
results. It showed that the phage effect to decrease bacterial load was limited and did not 
significantly improve the infection. In their discussion they point out that an immune response 
from the cows were seen in milk by high levels of somatic cell count. Somehow, the S. aureus 
infected and phage treated udders reacted strongly to this treatment immunologically (Gill et 
al., 2006). In addition there might have been other aspects of how bacteria could resist phage 
infections. Abedon et al., (2012) listed in an article some mechanisms of phage-resistance in 
bacteria. Bacteria can for example change their genome and in following generations process 
a type of adaptive immunity (Abedon et al., 2012).  
In all included articles on phage therapy against S. aureus in biofilm the one of Rahman et al., 
(2011), Kaur et al. (2016) and Hsieh et al. (2011) bactericidal results were given. These 
results have been fortified lately. In a review Gutiérrez et al. (2018) explained how the phage 
protein affects biofilm. Using lytic proteins from phages, both biofilm on endocarditis and 
general bacteraemia, might be cured. Another point they made was the possibility to remodel 
these protein structures using bio techniques. This review also points out that the development 
of phage-resistance will be a future concern for phage therapy (Gutiérrez et al., 2018).  
Several of these experiments had more extensive bactericidal results when phage therapy was 
combined with antibiotics than used as single treatment. It might be a result of phage therapy 
and antibiotics killing bacteria laterally. If the antibiotics kill a part of the present bacteria and 
phage therapy one part they might as well benefit from each other. This was discussed as a 
possibility to why several of the studies presented lowered bacterial load when phage therapy 
was combined with antibiotics than from the phage therapy alone. Comeau et al. (2007) 
concluded the same when proving that combined antibiotics and phage therapy were more 
bactericidal together. They reported this to be the case even when sub-lethal doses of 
antibiotics and phage therapy united were used (Comeau et al., 2007). 
All of the studies reported here with mice as model animals gave positive results on 
bactericidal effect. The common denominator was defined bacterial strains and known phage 
strains. This was a notion that Kaźmierczak et al. (2014) also made in a review, that it was 
crucial to select the right phage for the bacteria present. It might have been a critical factor of 
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success in the reported tests in this essay (Kaźmierczak et al., 2014). Importance in selecting 
and matching the right phages for certain bacterial strains to be used in therapy was also 
confirmed by Abedon et al., (2011). Several companies in multiple countries provide phage 
cocktails on the market. Abedon et al., (2011) mentions that in some institutions, using a lot 
of phage therapy, the mixtures are continuously updated to meet bacterial changes in 
genotypes (Abedon et al., 2011).  
A somehow complementing result compared to those given by this essay was published in 
2016. Chadha et al. (2016) then concluded from a test with phage therapy on the bacterium 
Klebsiella pneumonie that ´cocktail´s with several types were more efficient than a single 
phage strain (Chadha et al., 2016). Some of the tests conducted and referred to in this 
literature overview used monophage therapy and some used ´cocktail´s.  
Discussion on essay 
The aim of this study was to, by investigating the literature available, see if phage therapy 
could be used in clinical treatment against S. aureus. Already the search result could tell that 
there were a lot of studies done on the subject. The large number of articles found on the 
database PubMed showed that this specific bacteria and phage therapy has been widely 
observed. The answer from the thesis would be that phage therapy could be used against S. 
aureus under certain defined conditions.  
Some of these results can be discussed further though. The experiments with phage therapy to 
S. aureus strains from dairy cows with mastitis on mice all gave bactericidal answers. The 
field trial on cows on the other hand did not. This might be since they suffered from 
subclinical mastitis, an indication that the bacterial load was too low for the phage to reach 
their potential. Another possibility is the difference in quantity and quality of milk in mouse 
mammary gland and a cow´s udder. There is a difference of how phages can reach a site of 
infection in a cow´s udder filled with milk and a small mouse with considerably smaller 
amounts of liquid. Comparing the difference in composition and compounds of protein-, fat- 
and carbohydrates- ratio in milk from mice and cows, the treatment and phage suspension 
might differ as well.    
The results that are seemingly closest to advancing into field trials of those presented here 
might be the use of phages against biofilm formation. It could be used on surfaces and on 
delimited infected locations as in orthopaedic surgery. Possibly the administration on surfaces 
could be more direct and phages could be administered directly.   
The conclusion is that bactericidal effects have been proven by phages against S. aureus in 
vitro and in vivo on laboratory level. The one field trial on subclinical mastitis cows referred 
to could not confirm significant bactericidal effect in favour of phage treatment to controls. 
Meanwhile in Russia, Georgia, US and China for example phages are a medical product on 
the market. This means ultimately that even if phage therapy is not an everyday choice in 
medicine there are several ´cocktail´ choices available for use in clinic. 
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